stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Total debt
ImmunityBio, Inc.'s total debt at the end of fiscal 2025 was $477.1M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $774.4M. Over the past ten years it has ranged from $2.4M (fiscal 2017) to $681.5M (fiscal 2023); the current reading is higher than 70% of that period. ImmunityBio, Inc. ranks 18th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $477.1M | 3.29% |
| FY2024 | $461.9M | (32.23%) |
| FY2023 | $681.5M | 1.24% |
| FY2022 | $673.2M | 10.61% |
| FY2021 | $608.6M | 132.93% |
| FY2020 | $261.3M | 1,659.66% |
| FY2019 | $14.8M | 114.88% |
| FY2018 | $6.9M | 192.92% |
| FY2017 | $2.4M | (7.82%) |
| FY2016 | $2.6M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $774.4M | 14.15% |
| Mar 2026 | $678.4M | 42.19% |
| Dec 2025 | $477.1M | (4.73%) |
| Sep 2025 | $500.8M | 1.77% |
| 36 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement